- Release Date: 24/06/15 08:33
- Summary: FLLYR: PEB: Adjustment to Pacific Edge's Preliminary Financial Results
- Price Sensitive: No
- Download Document 3.69KB
PEB 24/06/2015 08:33 FLLYR PRICE SENSITIVE REL: 0833 HRS Pacific Edge Limited FLLYR: PEB: Adjustment to Pacific Edge's Preliminary Financial Results 24 June 2015 ADJUSTMENT TO PACIFIC EDGE'S PRELIMINARY FINANCIAL RESULTS Pacific Edge advises that an adjustment has been made to its financial statements for the year ended 31st March 2015, to include a provision for the payment of up to $500,000 for the settlement reached with the FMA as announced on the 25th of May. A provision was not included in the preliminary results announced on the 28th of May due to the timing of the decision with the FMA and the release of the preliminary results three days later. The company remains focused on driving awareness and commercial sales of its Cxbladder tests in all of its targeted markets. This adjustment increases the Net Loss for the period to $11.229m from the reported $10.729m. Pacific Edge's full financial results will be released on the 29th of June 2015. For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 ABOUT Cxbladder Triage Cxbladder Triage is a novel molecular test that combines the power of the genomic biomarkers with extra phenotypic and clinical risk factors to accurately identify and remove patients with hematuria who have a low probability of bladder cancer, from needing to have a full-urological work-up. This is a tool for use by clinicians and physicians in the primary evaluation and is intended to reduce of the number of patients needing an expensive and invasive work-up for urothelial cancer. www.cxbladder.com ABOUT Cxbladder Detect Cxbladder Detect is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of urine. Cxbladder Detect is commercially available in New Zealand, Australia and the USA. Cxbladder Detect is available in the USA and NZ as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories, providing physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists with an effective adjunct to cystoscopy. The Cxbladder Detect cancer detection test has been validated by a multi-centre, international clinical study. www.cxbladder.com ABOUT Bladder Cancer Globally, bladder cancer has the 9th highest incidence and the 4th highest incidence for men. One of the early symptoms of bladder cancer is the presence of blood in the urine, haematuria. People with haematuria often present to their general practitioner before being referred on to a urologist. Bladder cancer has a very high recurrence rate of approximately 50%-70% with up to 30% of these recurring as later stage tumours. However, bladder cancers are highly treatable, especially if detected in the early stages when there is a much higher probability of survival. Timely detection and regular surveillance and monitoring of this cancer is a key element of the clinical process and of the individual's annual healthcare plan. ABOUT Pacific Edge Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests. It's first commercial product, Cxbladder Detect, is now being actively marketed to physicians and clinicians in New Zealand, Australia, and the USA through the company's wholly owned subsidiaries and selected commercial partners. www.pacificedge.co.nz www.pacificedgedx.com End CA:00266073 For:PEB Type:FLLYR Time:2015-06-24 08:33:40
- Forums
- NZX - By Stock
- PEB
- Ann: FLLYR: PEB: Adjustment to Pacific Edge's Preliminary Financial Results
Ann: FLLYR: PEB: Adjustment to Pacific Edge's Preliminary Financial Results
Featured News
Add PEB (NZSX) to my watchlist